Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019)

Avalo Therapeutics' Finished Goods history spans 3 years, with the latest figure at $46705.0 for Q4 2019.

  • For Q4 2019, Finished Goods fell 90.62% year-over-year to $46705.0; the TTM value through Dec 2019 reached $46705.0, down 90.62%, while the annual FY2019 figure was $46705.0, 90.62% down from the prior year.
  • Finished Goods reached $46705.0 in Q4 2019 per AVTX's latest filing, down from $497949.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $560499.0 in Q4 2017 to a low of $46705.0 in Q4 2019.
  • Average Finished Goods over 3 years is $368384.3, with a median of $497949.0 recorded in 2018.
  • Peak YoY movement for Finished Goods: dropped 11.16% in 2018, then plummeted 90.62% in 2019.
  • A 3-year view of Finished Goods shows it stood at $560499.0 in 2017, then dropped by 11.16% to $497949.0 in 2018, then tumbled by 90.62% to $46705.0 in 2019.
  • Per Business Quant, the three most recent readings for AVTX's Finished Goods are $46705.0 (Q4 2019), $497949.0 (Q4 2018), and $560499.0 (Q4 2017).